Lilly's COVID-19 Antibodies in Development
Until now, all potential medicines in human studies to treat COVID-19 have been repurposed – medicines approved or studied for other diseases. Lilly believes antibody therapies may hold promise because they’re designed specifically to attack this coronavirus. They may be particularly important for groups hardest hit by the disease, such as the elderly and those with compromised immune systems. Neutralizing antibodies, if shown to be safe and effective and approved by regulatory authorities, could be an important bridge to widely available vaccines.
Lilly intends to test both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19.
View CEO Dave Ricks' letter about "Lilly's Principles of COVID-19 Antibody Therapy Pricing and Access"
View Lilly's Neutralizing Antibodies and COVID-19 fact sheet
Download photos of Lilly's antibody manufacturing:
Press Releases and Statements:
Disclaimer About Antibodies in Development
This contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about antibodies as potential treatments for COVID-19, and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that an antibody, or combination of antibodies, will prove to be an effective treatment or preventative for COVID-19. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements.